← Back to Search

Capecitabine + Radiotherapy for Breast Cancer

Phase 1
Waitlist Available
Led By Bapsi Chakravarthy, MD
Research Sponsored by A Bapsi Chakravarthy, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 7 months
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a combination of a chemotherapy drug (capecitabine) and radiation therapy for patients with breast cancer that doesn't respond to standard treatments. The treatment aims to attack cancer cells more effectively by disrupting their DNA and using radiation to destroy them. Capecitabine is an oral chemotherapy drug that has shown effectiveness in combination with other treatments, such as docetaxel, in improving survival rates for breast cancer patients.

Eligible Conditions
  • Breast cancer
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 7 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Assess tolerability
Characterize radiation dermatitis secondary to concurrent capecitabine-radiotherapy
Completion of exploratory assessments
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Concurrent Adjuvant Capecitabine and RadiotherapyExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Capecitabine
2013
Completed Phase 3
~4280
Radiotherapy
2017
Completed Phase 3
~2610

Find a Location

Who is running the clinical trial?

A Bapsi Chakravarthy, MDLead Sponsor
Bapsi Chakravarthy, MDPrincipal Investigator - Vanderbilt Medical Center
Vanderbilt-Ingram Cancer Center

Media Library

Radiotherapy Clinical Trial Eligibility Overview. Trial Name: NCT03958721 — Phase 1
Breast cancer Research Study Groups: Concurrent Adjuvant Capecitabine and Radiotherapy
Breast cancer Clinical Trial 2023: Radiotherapy Highlights & Side Effects. Trial Name: NCT03958721 — Phase 1
Radiotherapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT03958721 — Phase 1
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top